High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2105-2116

  Atkins, Michael B ^a   Lotze, Michael T ^a   Dutcher, Janice P ^a   Fisher, Richard I ^a   Weiss, Geoffrey ^a   Margolin, Kim ^a   Abrams, Jeff ^a   Sznol, Mario ^a   Parkinson, David ^a   Hawkins, Michael ^a   Paradise, Carolyn ^a   Kunkel, Lori ^a   Rosenberg, Steven A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CARDIOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MALE; MELANOMA; METASTASIS; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033024863     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2105     Document Type: Article

References (50)

1. Balch CM, Reintgen DS, Kirkwood JM, et al: Cutaneous melanoma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 1947-1994
2. Balch CM, Soong S-J, Murad TM, et al: A multi-factorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastasis. J Clin Oncol 1:126-134, 1983
3. Earth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995
4. Ryan L, Kramar A, Borden E: Prognostic factors in metastatic melanoma. Cancer 71:2995-3005, 1993
5. Hill GJ 2d, Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma: IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53:1299-1305, 1984
6. McClay EF, Mastrangelo MJ, Berd D, et al: Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three clinical trials. Int J Cancer 50:553-556, 1992
7. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408, 1991
8. Thompson D, Adena M, McLeod GRC: Interferon alfa-2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial, QMP8704. Melanoma Res 3:133-138, 1993
9. Bajetta E, Di Leo A, Zampino M, et al: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2A in the treatment of advanced melanoma. J Clin Oncol 12:806-811, 1994
10. Kirkwood JM, Ernstoff MS, Giuliano A, et al: Interferon-2a and dacarbazine in melanoma. J Natl Cancer Inst 82:1062-1063, 1990
11. Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2083-2090, 1996
12. Falkson CI, Ibrahim J, Kirkwood J, et al: Phase III trial of dacarbazine versus dacarbazine with interferon-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751, 1998
13. Atkins MB: The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers, in Kirkwood JM (ed): Molecular Diagnosis, Prevention & Therapy of Melanoma. New York, NY, Marcel Dekker, 1998, pp 219-251
14. Morgan DA, Ruscetti FW, Gallo R: Selective in vitro growth of T lymphocytes for normal human bone marrows. Science 193:1007-1008, 1976
15. Taniguchi T, Matsui H, Fujita T, et al: Structure and expression of cloned cDNA for human interleukin-2. Nature 302:305-310, 1983
16. Rosenberg SA, Mule JJ, Speiss PJ, et al: Regression of established pulmonary metetastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169-1188, 1985
17. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985
18. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
19. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
20. Parkinson D, Abrams J, Wiernik P, et al: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 8:1650-1656, 1990
21. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994
22. McCabe MS, Stablein D, Hawkins MJ, et al: The Modified Group C experience: Phase III randomized trials of IL-2 vs. IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 10:213a, 1991 (abstr)
23. Oken MM, Creech R, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Argawala SS, Kirkwood JM: Interferon in melanoma. Curr Opin Oncol 8:167-174, 1996
26. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996
27. Chapman PB, Parkinson DR, Kirkwood JM: Biologic therapy, in Balch CM, Houghton AN, Sober AJ, et al (eds): Cutaneous Melanoma (ed 3). St Louis, MO, Quality Medical Publishing, 1997, pp 419-436
28. Ahmann DL, Creagan ET, Han RG, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63:224-227, 1989
29. Buzaid AC, Bedikian A, Houghton AN: Systemic chemotherapy and biochemotherapy, in Balch CM, Houghton AN, Sober AJ, et al (eds): Cutaneous Melanoma (ed 3). St Louis, MO, Quality Medical Publishing, 1997, pp 405-418
30. Margolin K: The clinical toxicities of high-dose interleukin-2, in Atkins MB, Mier JW (eds): Therapeutic Applications of Interleukin-2 (ed 1). New York, NY, Marcel Dekker, 1993, pp 331-362
31. Schwartzentruber DJ: Biologic therapy with interleukin-2: Clinical applications - Principles of administration and management of side effects, in DeVita V, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer (ed 2), Philadelphia, PA, Lippincott, 1995, pp 235-249
32. Klempner MS, Noring R, Mier JW, et al: An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 322:959-965, 1990
33. Klempner MS, Snydman DR: Infectious complications associated with interleukin-2, in Atkins MB, Mier JW (eds): Therapeutic Applications of Interleukin-2 (ed 1). New York, NY, Marcel Dekker, 1993, pp 409-424
34. Mier JW, Vachino G, Klempner MS, et al: Inhibition of interleukin-2 induced tumor necrosis factor release by dexamethasone: Prevention of an acquired neutrophil chemotactic defect and differential suppression of interleukin-2 associated side effects. Blood 76:1933-1940, 1990
35. Trehu EG, Mier JW, Shapiro L, et al: Aphase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res 2:1341-1351, 1996
36. DuBois JS, Trehu EG, Mier JW, et al: Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 15:1052-1062, 1997
37. McDermott D, Trehu E, DuBois J, et al: Phase I clinical trial of the soluble IL-1 receptor either alone or in combination with high-dose IL-2 in patients with advanced malignancies. Clin Cancer Res 5:1203-1213, 1998
38. Margolin K, Weiss G, Dutcher J, et al: Prospective randomized trial of lisofylline (CT1501 R) for the modulation of interleukin-2 (IL-2) toxicity. Clin Cancer Res 3:565-572, 1997
39. Kemeny MM, Ochani M, Tracey KJ: CNI-1493 blocks the toxicity of interleukin-2 (IL-2) but does not disturb the antineoplastic response. Proc Am Soc Clin Oncol 15:272a, 1996 (abstr 723)
40. Sleijfer DT, Janssen RAJ, Butler J, et al: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119-1123, 1992
41. tzpodien J, Lopez HE, Kirchner H, et al: Multi-institutional home therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13:497-501, 1995
42. Yang JC, Topalian SL, Parkinson D, et al: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576, 1994
43. Dutcher J, Atkins MB, Fisher RI, et al: IL-2 based therapy in metastatic renal cell cancer (MRCC): Cytokine Working Group (CWG) experience. Proc Am Soc Clin Oncol 16:327a, 1997 (abstr 1166)
44. Anderson CM, Buzaid A, Legha S: Systemic treatments for advanced cutaneous melanoma. Oncology 9:1149-1158, 1995
45. Legha SS, Sigrid R, Eton O, et al: Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 3:S9-S15, 1997 (suppl 1)
46. McDermott DF, Mier JW, Lawrence DP, et al: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), interleukin-2 (IL-2) and interferon alpha-2b (IFN) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 17:507a, 1998 (abstr 1956)
47. O'Day SJ, Boasberg P, Guo M, et al: Phase II trial of concurrent biochemotherapy (c-BC) with decrescendo interleukin-2 (d-IL-2), tamoxifen (T), and G-CSF support in patients with metastatic melanoma (MM). Proc Am Soc Clin Oncol 16:490a, 1997 (abstr 1763)
48. Thompson JA, Gold PJ, Markowitz DR, et al: Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3:S29-S34, 1997 (suppl 1)
49. Atkins MB: Biochemotherapy for metastatic melanoma: The rationale for the intergroup phase III trial. Biother Consid Oncol Nurses 2:1-4, 1997
50. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998